Are we living in the end of the blockbuster drug era?

Drug News and Perspectives

Volumn 23, Issue 10, 2010, Pages 670-684

  Debnath, Bikash ^a   Al Mawsawi, Laith Q ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; AMFEBUTAMONE; AMLODIPINE BESYLATE; ATORVASTATIN; AZITHROMYCIN; BETA1A INTERFERON; BEVACIZUMAB; CETUXIMAB; CLOPIDOGREL; CONSENSUS INTERFERON; DONEPEZIL; DORNASE ALFA; ENOXAPARIN; ESCITALOPRAM; ETANERCEPT; FENTANYL; FLUINDOSTATIN; FLUTICASONE PROPIONATE PLUS SALMETEROL; GENERIC DRUG; HUMAN INSULIN; IMIGLUCERASE; INFLIXIMAB; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INTERFERON BETA SERINE; LAMOTRIGINE; LANSOPRAZOLE; LOSARTAN POTASSIUM; METOPROLOL SUCCINATE; MEVINOLIN; MONTELUKAST; NATALIZUMAB; NILOTINIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OLANZAPINE; OMEPRAZOLE; PALIVIZUMAB; PIOGLITAZONE; PRAVASTATIN; QUETIAPINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISPERIDONE; RITUXIMAB; ROSUVASTATIN; SIMVASTATIN; TRASTUZUMAB; UNINDEXED DRUG; VALSARTAN; VENLAFAXINE;

COST CONTROL; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; LAW; PATENT; PERSONALIZED MEDICINE; REVIEW; COMMERCIAL PHENOMENA; DRUG COST; DRUG DESIGN; ECONOMIC ASPECT; ECONOMICS; HUMAN; UNITED STATES;

COMMERCE; DRUG COSTS; DRUG DESIGN; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HUMANS; PATENTS AS TOPIC; UNITED STATES;

EID: 79954430048     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2010.23.10.1506088     Document Type: Review

References (81)

1. URCH Publishing provides a review of the global pharmaceutical market in 2008. URCH Publishing, November 9, 2008. http://www.urchpublishing.com/articles/ urch-publishing-provides-a-review-of-the-global-pharmaceutical-market-in-2008. html. Accessed November 18, 2010.
2. Cutler, D.M. The demise of the blockbuster? N Engl J Med 2007, 356(13): 1292-3.
3. Jack, A. The fall of the world's best-selling drug. Financial Times, November 28, 2009. http://www.ft.com/cms/s/2/d0f7af5cd7e6-11de-b578- 00144feabdc0.html. Accessed November 18, 2010.
4. The Pharm Exec 50. Pharmaceutical Executive, May 2010. http://pharmexec.find-pharma.com/pharmexec/data/article-standard//pharmexec/ 222010/671415/article.pdf. Accessed November 17, 2010.
5. IMS Health Midas, December 2009.
6. Earnings Preview: Abbott Laboratories to report 4Q. Business Week, January 25, 2010. http://www.businessweek.com/ap/financialnews/D9DESIMG0.htm. Accessed.
7. Bruderlin-Nelson, C. Pfizer's Lipitor patent term secure. Fierce Pharma, January 7, 2009. http://www.fiercepharma.com/story/pfizers-lipitor-patent-term- secure/2009-01-07. Accessed November 17, 2010.
8. Patent terms extended under 35 USC §156. United States Patent and Trademark Office, http://www.uspto.gov/patents/resources/terms/156.html. Accessed November 17, 2010.
9. Method, K. Going, going, gone: Patents set to expire soon on many brand-name drugs. Drug Topics, August 10, 2009. http://drugtopics. modernmedicine.com/drugtopics/article/articleDetail.jsp?id=617015&sk= &date=&pageID=2. Accessed November 17, 2010.
10. US FDA Orange Book. U.S. Food & Drug Administration: 2009.
11. Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 2009, 8(12): 959-68.
12. Carroll, J. Pharma pipelines mired by poor productivity, shrinking R&D budgets. Fierce Biotech, June 28, 2010. http://www.fierce-biotech.com/ story/r-d-budgets-slide-declining-output-mires-pharma-pipeline/2010-06-28. Accessed November 17, 2010.
13. Hirschler, B. Data shows declining productivity in drug R&D. Reuters, June 27, 2010. http://www.reuters.com/article/idCALDE65O10E20100627?rpc=44. Accessed November 17, 2010.
14. Mossinghoff, G.J. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food Drug Law J 1999, 54(2): 187-94.
15. Long, D. U.S. pharmaceutical market trends: tremendous slowdown. IMS Health, July 2009. http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= bd34c71e81a32210VgnVCM100000ed152ca2RCRD&vgnextfmt=default. Accessed December 2, 2010.
16. Aitken, M., Berndt, E.R., Cutler, D.M. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood) 2009, 28(1): w151-60.
17. IMS Health. National Sales Perspectives, Branded generics disaggregated. May 2010.
18. IMS Health. National Prescription Audit, Branded generics disaggregated. June 2010.
19. IMS Health reports annual global generics prescription sales growth of 3.6 percent, to $78 billion [news release]. IMS Health, December 10, 2008. http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= 2943d52288d1e110VgnVCM100000ed152ca2RCRD&vgnextchannel= 41a67900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default. Accessed November 22, 2010.
20. IMS Health: annual global generics prescription sales growth declines. All Business, December 18, 2008. http://www.allbusiness.com/pharmaceuticals- biotechnology/pharmaceutical/12177752-1.html. Accessed November 22, 2010.
21. DeArment, A. Generics continue to brand prescription drug growth. Drug Store News 2009, 31(10): 100.
22. Global market for generic drugs to reach $129 billion in 2014 [news release]. BCC Research, October 12, 2009. http://www.bccresearch.com/ pressroom/PHM009E.html. Accessed November 22, 2010.
23. Report: Booming US Generic Drug Market. RNCOS E-Services Pvt. Ltd.: 2009.
24. Feldman, C. Generic drug superstars. Fortune/CNNMoneycom, August 5, 2009. http://money.cnn.com/2009/08/05/news/companies/top-generic-drugs.fortune/index. htm. Accessed November 22, 2010.
25. 2009 Medco Drug Trend Report. Medco, http://medco.mediaroom.com/file.php/ 177/2009+DRUG+TREND+REPORT.pdf. Accessed November 26, 2010.
26. GPhA says new Harris poll confirms that consumers believe generic medicines are the right choice for better health and increased savings [news release]. Generic Pharmaceutical Association, January 26, 2009. http://www.gphaonline.org/media/press-releases/2009/02/12/gpha-says-new-harris- pollconfirms-consumers-believe-generic-medicin. Accessed November 26, 2010.
27. Lamb, E. Top 200 Drugs of 2008. Pharmacy Times, May 15, 2009. http://www.pharmacy-times.com/issue/pharmacy/2009/2009-05/RxFocusTop200Drugs- 0509. Accessed November 26, 2010.
28. Generic pharmaceuticals saved $734 billion over last decade [news release]. Generic Pharmaceutical Association, May 7, 2009. http://www. gphaonline.org/media/press-releases/2009/generic-pharmaceuticalssaved-734- billion-over-last-decade. Accessed November 26, 2010.
29. OGD funding. Generic Pharmaceutical Association, March 18, 2009. http://www.gphaonline.org/issues/ogd-funding. Accessed November 29, 2010.
30. Johnson, A., Greil, A. Pfizer, Novartis disclose deals in generic drugs. The Wall Street Journal, May 21, 2009. http://online.wsj.com/article/ SB124282209997539061.html. Accessed November 26, 2010.
31. Herper, M. Living without blockbusters. Forbes Magazine, November 16, 2009. http://www.forbes.com/forbes/2009/1116/companies-sanofi-aventis-pharm- living-without-blockbusters.html. Accessed November 26, 2010.
32. Sandoz to acquire EBEWE Pharma specialty generics business, improving access for patients worldwide to injectable cancer drugs [news release]. Novartis, May 20, 2009. http://www.novartis.com/newsroom/media-releases/en/2009/ 1316498.shtml. Accessed November 26, 2010.
33. Wardell, J. AstraZeneca partners with Torrent Pharmaceuticals. Drug Discovery & Development, March 11, 2010. http://www.dddmag.com/news- AstraZeneca-Partners-With-Torrent-Pharmaceuticals-31110.aspx. Accessed November 26, 2010.
34. Somvanshi, K.K., Mahesh, P. Hospira Inc in agreement with Orchid Chemicals to acquire generic injectable. The Economic Times, December 20, 2009. http://economictimes.indiatimes.com/features/the-sunday-et/companies/ Hospira-Inc-in-agreement-with-Orchid-Chemicals-to-acquire-generic-injectable/ articleshow/5357307.cms. Accessed November 26, 2010.
35. Staton, T. Pfizer aims for Japanese generics market. Fierce Pharma, November 19, 2009. http://www.fiercepharma.com/story/pfizeraims-japanese- generics-market/2009-11-19. Accessed November 26, 2010.
36. Carroll, J. Daiichi Sankyo acquires Ranbaxy in $4.6B deal. Fierce Biotech, June 11, 2008. http://www.fiercebiotech.com/story/daiichisankyo- acquires-ranbaxy-4-6b-deal/2008-06-11#ixzz0cXr7qIax. Accessed November 26, 2010.
37. Duh, M.S., Greenberg, P.E., Antràs, L. Drug safety and risk management practice. What drug companies can do. Update 2008, Issue 3: 35-8.
38. Rugnetta, M., Kramer, W. Paving the way for personalized medicine. Science Progress, September 14, 2009. http://www.science-progress.org/2009/09/ personalized-medicine/. Accessed November 26, 2010.
39. 232 billion personalized medicine market to grow 11 percent annually, says Pricewater-houseCoopers [news release]. Pricewater-houseCoopers, December 8, 2009. http://www.pwc.com/US/en/press-releases/2009/232-Billion-personalized- medicine-market-to-grow.jhtml. Accessed November 26, 2010.
40. Cascorbi, I. The promises of personalized medicine. Eur J Clin Pharmacol 2010, 66(8): 749-54.
41. Abrahams, E. Personalized medicine realizing its promise. Gen Eng Biotech News 2009, 29(15): 70-3.
42. Pene, F., Courtine, E., Cariou, A., Mira, J.P. Toward theragnostics. Crit Care Med 2009, 37(1 Suppl): S50-8.
43. Center for Drug Evaluation and Research (CDER), United States Food and Drug Administration (FDA). http://www.fda.gov/drugs.
44. Hughes, B. 2009 FDA drug approvals. Nat Rev Drug Discov 2010, 9(2): 89-92.
45. Arnst, C., Barrett, A., Arndt, M., Carey, J. The waning of the blockbuster drug. Business Week, October 18, 2004. http://www.businessweek.com/ magazine/content/04-42/b3904034-mz011.htm. Accessed November 29, 2010.
46. Sopko, M.A., Jr., Ehret, M.J., Grgas, M. Desvenlafaxine: another "me too" drug? Ann Pharmacother 2008, 42(10): 1439-46.
47. Serrao, E., Odde, S., Ramkumar, K., Neamati, N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6: 25.
48. Lind, T., Rydberg, L., Kyleback, A. et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000, 14(7): 861-7.
49. Edwards, S.J., Lind, T., Lundell, L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006, 24(5): 743-50.
50. Hensley, S. Drugmakers' me-too medicines face tough customers. The Wall Street Journal, May 27, 2008. http://blogs.wsj.com/health/2008/05/27/drugmakers- me-too-medicines-face-tough-customers/. Accessed November 29, 2010.
51. Wertheimer, A.I., Santella, T.M. Pharmocoevolution: the benefits of incremental innovation. Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH), March 17, 2005. http://www. who.int/ intellectualproperty/submissions/Pharmacoevolution.pdf. Accessed November 29, 2010.
52. World Preview 2016. EvaluatePharma, http://www.evaluatepharma.com/ EvaluatePharma-World-Preview-2016.aspx.
53. Schellekens, H. The immunogenicity of biopharmaceuticals. Neurology 2003, 61(9 Suppl 5): S11-2.
54. Schellekens, H. Biosimilar therapeutics-what do we need to consider? NDT Plus 2009, 2(Suppl. 1): i27-i36.
55. Hincal, F. An introduction to safety issues in biosimilars/follow-on biopharmaceuticals. J Med Chem Biol Radiol Def 2009, 7: 1-18.
56. Emerging health care issues: follow-on biologic drug competition. Federal Trade Commission Report, June 2009. http://www.ftc.gov/os/2009/06/ P083901biologicsreport.pdf. Accessed November 29, 2010.
57. Begley, C. Opening the door for biogenerics. The Washington Times, September 18, 2009. http://www.washingtontimes.com/news/2009/sep/18/opening-the- door-for-biogenerics/Accessed November 29, 2010.
58. Kennedy, V.B. Who wins, who loses with biogenerics. Market Watch, September 1, 2009. http://www.marketwatch.com/story/who-wins-who-loses-with- biogenerics-2009-08-28. Accessed November 29, 2010.
59. Market research report: Biosimilars (2009-2014). MarketsandMarkets, September 2009. http://www.marketsandmarkets.com/Market-Reports/biosimilars-40. html.
60. Study by leading economist identifies potential for $378 billion of savings from follow on biologics [news release]. Insmed, Inc., February 11, 2008. http://investor.insmed.com/releasedetail.cfm?ReleaseID=293143. Accessed November 29, 2010.
61. Walker, J. Deal watch: M&A activity in 2009. Nat Rev Drug Discov 2010, 9(2): 95.
62. Goldstein, J. Pfizer-Wyeth deal wraps up; layoffs to follow. The Wall Street Journal, October 15, 2009.
63. Sowlay, M., Lloyd, S. The current M&A environment and its strategic implications for emerging biotherapeutics companies. J Commer Biotechnol 2010, 16(2): 109-19.
64. Staton, T. Pharma drops again in public opinion. FiercePharma, June 30, 2008. http://www.fiercepharma.com/story/pharma-drops-again-public-opinion/2008- 06-30. Accessed November 29, 2010.
65. Harris, G. Pfizer pays $2.3 billion to settle marketing case. The New York Times, September 2, 2009. http://www.nytimes.com/2009/09/03/business/ 03health.html?-r=1. Accessed November 29, 2010.
66. Wilson, D. For $520 million, AstraZeneca will settle case over marketing of a drug. The New York Times, April 26, 2010. http://www.nytimes.com/ 2010/04/27/business/27drug.html?-r=2&partner=rss&emc=rss. Accessed November 29, 2010.
67. Berkowitz, A.C., Goddard, D.M. Novel drug delivery systems: future directions. J Neurosci Nurs 2009, 41(2): 115-20.
68. Hernandez-Hernandez Fde, L., Rodriguez, M.H. [Biotechnological advances in infectious diseases diagnosis]. Salud Publica Mex 2009, 51(Suppl. 3): S424-38.
69. Payne, K. Pharmacogenetics: towards the safe, effective and cost-effective use of medicines? Int J Pharm Pract, 18(Suppl. 2): 1-2.
70. Thierry, B. Drug nanocarriers and functional nanoparticles: applications in cancer therapy. Curr Drug Deliv 2009, 6(4): 391-403.
71. Chan, J.N., Nislow, C., Emili, A. Recent advances and method development for drug target identification. Trends Pharmacol Sci 2010, 31(2): 82-8.
72. IMS Health forecasts global pharmaceutical market growth of 5-7 percent in 2011, reaching $880 billion [news release]. IMS Health, October 6, 2010. http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f611019418c22a/?vgnextoid= 119717f27128b210VgnVCM100000ed152ca2RCRD&vgnextchannel= b5e57900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default. Accessed November 29, 2010.
73. Haberman, A.B. Obesity Drug Pipeline: Developing Therapies for a Complex Disease. Insight Pharma Reports, September, 2008.
74. Booming Global Obesity Drug Market. RNCOS, December, 2008. http://www.rncos.com/Report/IM166.htm.
75. Daly, R. Are any breakthrough drugs advancing through pipeline? Psychiatric News 2010, 45(16): 1-24.
76. Report: Medicines in Development for Mental Illnesses 2010. Pharmaceutical Research and Manufacturers of America (PhRMA), http://www.phrma.org/sites/phrma.org/files/attachments/Mental-2010.pdf. Accessed November 29, 2010.
77. Majoros, I.J., Williams, C.R., Becker, A., Baker, J.R., Jr. Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009, 1(5): 502-10.
78. Kurmi, B.D., Kayat, J., Gajbhiye, V., Tekade, R.K., Jain, N.K. Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 2010, 7(7): 781-94.
79. Modi, G., Pillay, V., Choonara, Y.E. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N Y Acad Sci 2010, 1184: 154-72.
80. Chun, Y.W., Webster, T.J. The role of nanomedicine in growing tissues. Ann Biomed Eng 2009, 37(10): 2034-47.
81. Brouwers, J., Brewster, M.E., Augustijns, P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 2009, 98(8): 2549-72.